J&J may put talc liabilities into new business that files bankruptcy

  • Johnson & Johnson (NYSE:JNJ) is exploring a plan to offload liabilities from its Baby Powder litigation into a newly created business that would then seek bankruptcy protection, Reuters reports.
  • J&J has not yet decided whether to actually pursue the bankruptcy plan, and it is not clear whether the company has retained restructuring lawyers to help explore the bankruptcy plan, according to the report.
  • The company faces legal actions from tens of thousands of plaintiffs alleging its Baby Powder and other talc products contained asbestos and caused cancer.
  • According to recent reports, the FDA has launched an investigation into why the cancer-causing agent benzene has been found in some samples of J&J's Neutrogena and Aveeno branded sunscreens.

    Tomorrow the American company Johnson & Johnson will publish its past quarter results. For this year Johnson & Johnson 's (located in New Brunswick) revenue will be around 94.48 billion USD. This is according to the average of the analysts' estimates. This is quite more than 2021's revenue of 82.58 billion USD.

    Historical revenues and results Johnson & Johnson plus estimates 2021

    aandelenanalyse

    The analysts expect for 2021 a net profit of 25.79 billion USD. For this year most of the analysts expect a profit per share of 9.67 USD. The price-earnings-ratio equals 18.03.

    Analysts expect a dividend of 4.17 USD per share. Johnson & Johnson 's dividend yield thus equals 2.39 percent. The average dividend yield of the health care companies equals a limited 1.45 percent.

    Newest target prices around 177 USD

    The latest 3 recommendations for the health care company were provided by Credit Suisse , ABN AMRO and KBC Securities.

    Based on the current number of outstanding shares Johnson & Johnson 's market capitalization 459.08 billion USD. 22

    Historical stock prices Johnson & Johnson

    fundamental data johnson&johnson

    At 15.40 the stock trades 0.39 percent lower at 174.39 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.